OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma
暂无分享,去创建一个
Chen Liu | David R Nelson | Xiangxuan Zhao | C. Tian | O. Ogunwobi | D. Nelson | W. Puszyk | Ton Wang | Chen Liu | Roniel Cabrera | Olorunseun O Ogunwobi | Xiangxuan Zhao | Changhai Tian | William M Puszyk | Mengde Cao | Ton Wang | M. Cao | R. Cabrera | Changhai Tian
[1] H. Lorenz,et al. A rapid and simple method for the isolation of apoptotic DNA fragments. , 1994, Nucleic acids research.
[2] R. Jove,et al. Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3 , 2010, Molecular Cancer Therapeutics.
[3] E. Raymond,et al. [Targeted therapies in hepatocellular carcinoma]. , 2010, Presse medicale.
[4] J. Crawford,et al. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. , 2007, Gastroenterology.
[5] S. Grant,et al. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. , 2007, Cancer research.
[6] V. Polyakov,et al. Fusion, Fragmentation, and Fission of Mitochondria , 2003, Biochemistry (Moscow).
[7] H. Yamaguchi,et al. Arsenic trioxide (As2O3) induces apoptosis through activation of Bax in hematopoietic cells , 2005, Oncogene.
[8] E. Thiel,et al. Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. , 2011, European journal of cancer.
[9] R. Gérolami,et al. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma. , 2011, Clinics and research in hepatology and gastroenterology.
[10] F. Grabellus,et al. Liver transplantation for metastasized extragastrointestinal stromal tumor: a case report and an overview of literature. , 2010, Transplantation proceedings.
[11] M. Bissonnette,et al. Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. , 2008, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[12] C. Wenner. Targeting mitochondria as a therapeutic target in cancer , 2012, Journal of cellular physiology.
[13] F. Aucejo,et al. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. , 2011, Oncology.
[14] C. Bartolozzi,et al. Complete response for advanced liver cancer during sorafenib therapy: Case Report , 2011, BMC gastroenterology.
[15] D. Chan. Mitochondria: Dynamic Organelles in Disease, Aging, and Development , 2006, Cell.
[16] M. Atkins,et al. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. , 2006, Cancer research.
[17] J. Llovet,et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.
[18] C. Trautwein,et al. Long-term survival of a HCC-patient with severe liver dysfunction treated with sorafenib. , 2010, World journal of hepatology.
[19] A. Mackensen,et al. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report. , 2010, Leukemia research.
[20] Y. Yamaoka,et al. Hepatic cellular responses to liver cancer: abnormalities in metabolism of mitochondria isolated from human liver involved with carcinoma. , 1974, Annals of surgery.
[21] S. Wilhelm,et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. , 2006, Methods in enzymology.
[22] Shikha Khatri,et al. Targeting bioenergetics to enhance cancer chemotherapy: Mitochondria SLP into apoptosis , 2009, Cancer biology & therapy.
[23] M. Fukuoka,et al. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. , 2010, Cancer research.
[24] L. Scorrano,et al. Prohibitin(g) cancer: aurilide and killing by Opa1-dependent cristae remodeling. , 2011, Chemistry & biology.
[25] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[26] B. Evers,et al. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. , 2010, Anticancer research.
[27] T. Cheng,et al. Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy. , 2011, Drug discovery today.
[28] B. Westermann. Mitochondrial dynamics in model organisms: what yeasts, worms and flies have taught us about fusion and fission of mitochondria. , 2010, Seminars in Cell and Developmental Biology.
[29] Jialin C. Zheng,et al. HIV‐infected macrophages mediate neuronal apoptosis through mitochondrial glutaminase , 2008, Journal of neurochemistry.
[30] W. Zong,et al. Gossypol induces Bax/Bak‐independent activation of apoptosis and cytochrome c release via a conformational change in Bcl‐2 , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[31] M. Santoro,et al. Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor β Gatekeeper Mutants , 2007, Clinical Cancer Research.
[32] Morel,et al. Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation , 2022 .
[33] Benedikt Westermann,et al. Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria. , 2008, Genes & development.
[34] J. Sarkaria,et al. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways , 2006, Molecular Cancer Therapeutics.
[35] K. Inaba. Nucleic acids and protein synthesis in cancer cell mitochondria. II. Amino acid incorporation into proteins of rat liver and hepatoma cell mitochondria. , 1968, Acta medicinae Okayama.
[36] Shaji K. Kumar,et al. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs , 2010, Oncogene.
[37] Jialin C. Zheng,et al. Mitochondrial Fragmentation Is Involved in Methamphetamine-Induced Cell Death in Rat Hippocampal Neural Progenitor Cells , 2009, PloS one.
[38] Robert E. Brown,et al. Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line. , 2010, International journal of clinical and experimental pathology.
[39] P. Marynen,et al. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. , 2007, Haematologica.
[40] Kuen-Feng Chen,et al. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. , 2010, Cancer research.
[41] E. Burns,et al. Cytoplasmic lipid in Ehrlich ascites tumor cells before and during recurrent growth. , 1971, Oncology.
[42] B. Hemmings,et al. Regulation of OPA1-mediated mitochondrial fusion by leucine zipper/EF-hand-containing transmembrane protein-1 plays a role in apoptosis. , 2009, Cellular signalling.
[43] L. Roberts. Sorafenib in liver cancer--just the beginning. , 2008, The New England journal of medicine.
[44] Y. Doki,et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. , 2010, Journal of hepatology.
[45] Y. Yoon,et al. Mitochondrial clustering induced by overexpression of the mitochondrial fusion protein Mfn2 causes mitochondrial dysfunction and cell death. , 2007, European journal of cell biology.
[46] Qizhi Gong,et al. Mitochondrial OPA1, apoptosis, and heart failure. , 2009, Cardiovascular research.
[47] Kuen-Feng Chen,et al. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. , 2010, Journal of hepatology.
[48] David S. Park,et al. Dissociating the dual roles of apoptosis‐inducing factor in maintaining mitochondrial structure and apoptosis , 2006, The EMBO journal.
[49] N. Hayashi,et al. The Bcl‐xL inhibitor, ABT‐737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib , 2010, Hepatology.